Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SCOTT D ROWLEY

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1366402893
CMS profile
914264
Location
HACKENSACK, NJ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$276.73

5 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $276.73 5

By paying entity

PY2022 · entire year · sorted by reported total

Paying entityAmountRecords
Janssen Biotech, Inc. $153.61 4
SANOFI-AVENTIS U.S. LLC $123.12 1

Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SCOTT D ROWLEY

NPI 1366402893 · CMS profile ID 914264

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

HACKENSACK, NJ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1366402893?year=2022&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SCOTT D ROWLEY, NPI 1366402893, CMS profile ID 914264. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1366402893?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). SCOTT D ROWLEY, NPI 1366402893, CMS profile ID 914264. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1366402893?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
SCOTT D ROWLEY, NPI 1366402893, CMS profile ID 914264, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1366402893?year=2022&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

5 matching records · $276.73 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 5 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–5 of 5.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Janssen Biotech, Inc. $90.9211/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886181479 CMS
SANOFI-AVENTIS U.S. LLC $123.1209/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939017005 CMS
Janssen Biotech, Inc. $20.7802/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886181495 CMS
Janssen Biotech, Inc. $19.8502/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886181491 CMS
Janssen Biotech, Inc. $22.0601/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886181485 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $102.98 1
PY2020 $29.94 2
PY2021 $61.48 3
PY2022 $276.73 5

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022
Generated from
OP_DTL_GNRL_PGYR2022_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2024 Principal investigator $14,700.00 2
PY2023 Principal investigator $7,095.00 6
PY2022 Principal investigator $23,109.60 13
PY2021 Principal investigator $33,469.97 35
PY2020 Principal investigator $49,540.67 34
PY2019 Recipient $1,736.14 2
PY2019 Principal investigator $149,688.27 56

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

58 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $1,573.14 12/11/2019 Covered Recipient Teaching Hospital
JERSEY SHORE UNIVERSITY MED CTR
PCYC-1140-IM No dispute reported 06/30/2026 673106333
Principal investigator 1 Incyte Corporation $49.60 11/23/2019 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
GRAVITAS 309-A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 666456583
Principal investigator 1 Incyte Corporation $49.84 11/23/2019 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
GRAVITAS 309-A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 666456585
Principal investigator 1 Incyte Corporation $50.00 11/23/2019 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
GRAVITAS 309-A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 666456589
Principal investigator 1 Incyte Corporation $124.90 11/22/2019 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
GRAVITAS 309-A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 666456363
Principal investigator 1 Incyte Corporation $175.15 11/22/2019 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
GRAVITAS 309-A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 666456365
Principal investigator 1 Incyte Corporation $25.00 11/22/2019 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
GRAVITAS 309-A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 666456581
Principal investigator 1 Incyte Corporation $50.00 11/22/2019 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
GRAVITAS 309-A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 666456587
Principal investigator 1 Incyte Corporation $110.00 11/22/2019 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
GRAVITAS 309-A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 666456591
Principal investigator 1 Incyte Corporation $130.00 11/22/2019 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
GRAVITAS 309-A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 666456593
Principal investigator 1 Incyte Corporation $600.50 11/22/2019 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
GRAVITAS 309-A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 666456595
Principal investigator 1 Incyte Corporation $471.00 11/21/2019 Non-covered Recipient Entity
DUKE UNIVERSITY MEDICAL CENTER
A Single Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid Refractory Acute Graft Versus Host Disease No dispute reported 06/30/2026 666510607
Principal investigator 1 Incyte Corporation $280.80 11/07/2019 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A Randomized, Double Blind, Placebo Controlled Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids for the Treatment of First Line Acute Graft Versus Host Disease No dispute reported 06/30/2026 666460951
Principal investigator 1 Incyte Corporation $750.00 10/22/2019 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
GRAVITAS 309-A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 666460981
Principal investigator 1 Incyte Corporation $14,000.00 10/22/2019 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
GRAVITAS 309-A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 666460983
Principal investigator 1 Incyte Corporation $2,650.00 10/22/2019 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
GRAVITAS 309-A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 666460985
Recipient NOVARTIS PHARMACEUTICALS CORPORATION $1,257.00 10/18/2019 Covered Recipient Physician RESEARCH RELATED PUBLICATIONS SUPPORT No dispute reported 06/30/2026 717204215
Principal investigator 1 Incyte Corporation $2.92 10/08/2019 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
GRAVITAS 309-A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 666456391
Principal investigator 1 Incyte Corporation $36.29 10/08/2019 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
GRAVITAS 309-A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 666456393
Principal investigator 1 Incyte Corporation $23.40 10/08/2019 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
GRAVITAS 309-A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 666456395
Principal investigator 1 Incyte Corporation $40.10 10/08/2019 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
GRAVITAS 309-A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 666456397
Principal investigator 1 Incyte Corporation $254.16 10/08/2019 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
GRAVITAS 309-A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 666456399
Principal investigator 1 Incyte Corporation $20.91 10/08/2019 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
GRAVITAS 309-A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 666456401
Principal investigator 1 Incyte Corporation $30.40 10/08/2019 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
GRAVITAS 309-A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 666456403
Principal investigator 1 Incyte Corporation $57.30 10/08/2019 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
GRAVITAS 309-A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 666456405
Principal investigator 1 Incyte Corporation $31.91 10/08/2019 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
GRAVITAS 309-A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 666456407
Principal investigator 1 Incyte Corporation $10.20 10/08/2019 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
GRAVITAS 309-A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 666456409
Principal investigator 1 Incyte Corporation $6.08 10/08/2019 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
GRAVITAS 309-A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 666456411
Principal investigator 1 Incyte Corporation $40.10 10/08/2019 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
GRAVITAS 309-A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 666456457
Principal investigator 1 Incyte Corporation $914.00 10/08/2019 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A Single Arm, Open Label, Phase 1 Study of Itacitinib in Combination With Calcineurin Inhibitor Based Interventions for the Prophylaxis of Graft Versus Host Disease GRAVITAS 119 No dispute reported 06/30/2026 666460969
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $15,240.20 09/18/2019 Covered Recipient Teaching Hospital
JERSEY SHORE UNIVERSITY MED CTR
PCYC-1140-IM No dispute reported 06/30/2026 673106205
Principal investigator 1 Incyte Corporation $2,666.00 09/05/2019 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A Single Arm, Open Label, Phase 1 Study of Itacitinib in Combination With Calcineurin Inhibitor Based Interventions for the Prophylaxis of Graft Versus Host Disease GRAVITAS 119 No dispute reported 06/30/2026 666460843
Principal investigator 1 Incyte Corporation $1,123.20 08/22/2019 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A Randomized, Double Blind, Placebo Controlled Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids for the Treatment of First Line Acute Graft Versus Host Disease No dispute reported 06/30/2026 666460841
Principal investigator 1 Incyte Corporation $19,953.00 08/05/2019 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A Single Arm, Open Label, Phase 1 Study of Itacitinib in Combination With Calcineurin Inhibitor Based Interventions for the Prophylaxis of Graft Versus Host Disease GRAVITAS 119 No dispute reported 06/30/2026 666460835
Principal investigator 1 Incyte Corporation $314.00 07/30/2019 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A Single Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid Refractory Acute Graft Versus Host Disease No dispute reported 06/30/2026 666477079
Principal investigator 1 Incyte Corporation $3,140.00 07/30/2019 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A Single Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid Refractory Acute Graft Versus Host Disease No dispute reported 06/30/2026 666477081
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $11,900.00 07/10/2019 Non-covered Recipient Entity
UNIVERSITY OF HACKENSACK MED.
Study of the Effect of a 5-Day Regimen of Study Drug on Peripheral Stem Cell Mobilization in Healthy Participants (GRANIX) No dispute reported 06/30/2026 685011853
Principal investigator 1 Incyte Corporation $3,798.00 06/11/2019 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A Single Arm, Open Label, Phase 1 Study of Itacitinib in Combination With Calcineurin Inhibitor Based Interventions for the Prophylaxis of Graft Versus Host Disease GRAVITAS 119 No dispute reported 06/30/2026 666460797
Principal investigator 1 Incyte Corporation $1,185.00 05/16/2019 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A Randomized, Double Blind, Placebo Controlled Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids for the Treatment of First Line Acute Graft Versus Host Disease No dispute reported 06/30/2026 666460707
Principal investigator 1 Shire North American Group Inc $2,600.00 05/07/2019 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF SHP620 COMPARED TO STANDARD OF CARE FOR THE TREATMENT OF CYTOMEGALOVIRUS CMV INFECTIONS THAT ARE RESISTANT OR REFRACTORY TO TREATMENT WITH GANCICLOVIR, VALGANCICLOVIR, FOSCARNET, OR CIDOFOVIR IN TRANSPLANT RECIPIENTS No dispute reported 06/30/2026 637704963
Principal investigator 1 Shire North American Group Inc $11,900.00 04/09/2019 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, ACTIVE-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF SHP620 COMPARED TO VALGANCICLOVIR FOR THE TREATMENT OF CYTOMEGALOVIRUS CMV INFECTION IN STEM CELL TRANSPLANT RECIPIENTS No dispute reported 06/30/2026 637704959
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $5,791.32 03/13/2019 Covered Recipient Teaching Hospital
JERSEY SHORE UNIVERSITY MED CTR
PCYC-1140-IM No dispute reported 06/30/2026 673105785
Principal investigator 1 Incyte Corporation $6,113.00 03/12/2019 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A Single Arm, Open Label, Phase 1 Study of Itacitinib in Combination With Calcineurin Inhibitor Based Interventions for the Prophylaxis of Graft Versus Host Disease GRAVITAS 119 No dispute reported 06/30/2026 666460749
Principal investigator 1 Incyte Corporation $2,205.00 03/12/2019 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A Single Arm, Open Label, Phase 1 Study of Itacitinib in Combination With Calcineurin Inhibitor Based Interventions for the Prophylaxis of Graft Versus Host Disease GRAVITAS 119 No dispute reported 06/30/2026 666460751
Principal investigator 1 Incyte Corporation $35.10 03/08/2019 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A Single Arm, Open Label, Phase 1 Study of Itacitinib in Combination With Calcineurin Inhibitor Based Interventions for the Prophylaxis of Graft Versus Host Disease GRAVITAS 119 No dispute reported 06/30/2026 666460171
Principal investigator 1 Incyte Corporation $28.65 03/08/2019 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A Single Arm, Open Label, Phase 1 Study of Itacitinib in Combination With Calcineurin Inhibitor Based Interventions for the Prophylaxis of Graft Versus Host Disease GRAVITAS 119 No dispute reported 06/30/2026 666460173
Principal investigator 1 Incyte Corporation $60.15 03/08/2019 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A Single Arm, Open Label, Phase 1 Study of Itacitinib in Combination With Calcineurin Inhibitor Based Interventions for the Prophylaxis of Graft Versus Host Disease GRAVITAS 119 No dispute reported 06/30/2026 666460175
Principal investigator 1 Shire North American Group Inc $4,454.00 03/05/2019 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, ACTIVE-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF SHP620 COMPARED TO VALGANCICLOVIR FOR THE TREATMENT OF CYTOMEGALOVIRUS CMV INFECTION IN STEM CELL TRANSPLANT RECIPIENTS No dispute reported 06/30/2026 637704951
Principal investigator 1 Incyte Corporation $7,834.00 02/21/2019 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A Single Arm, Open Label, Phase 1 Study of Itacitinib in Combination With Calcineurin Inhibitor Based Interventions for the Prophylaxis of Graft Versus Host Disease GRAVITAS 119 No dispute reported 06/30/2026 666460735
Principal investigator 1 Incyte Corporation $2,205.00 02/21/2019 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A Single Arm, Open Label, Phase 1 Study of Itacitinib in Combination With Calcineurin Inhibitor Based Interventions for the Prophylaxis of Graft Versus Host Disease GRAVITAS 119 No dispute reported 06/30/2026 666460737
Recipient NOVARTIS PHARMACEUTICALS CORPORATION $479.14 02/20/2019 Covered Recipient Physician RESEARCH RELATED PUBLICATIONS SUPPORT No dispute reported 06/30/2026 717204213
Principal investigator 1 Incyte Corporation $5,575.00 02/19/2019 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A Single Arm, Open Label, Phase 1 Study of Itacitinib in Combination With Calcineurin Inhibitor Based Interventions for the Prophylaxis of Graft Versus Host Disease GRAVITAS 119 No dispute reported 06/30/2026 666460733
Principal investigator 1 Incyte Corporation $4,671.00 02/07/2019 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A Randomized, Double Blind, Placebo Controlled Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids for the Treatment of First Line Acute Graft Versus Host Disease No dispute reported 06/30/2026 666460705
Principal investigator 1 Incyte Corporation $28.65 01/28/2019 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A Single Arm, Open Label, Phase 1 Study of Itacitinib in Combination With Calcineurin Inhibitor Based Interventions for the Prophylaxis of Graft Versus Host Disease GRAVITAS 119 No dispute reported 06/30/2026 666460159
Principal investigator 1 Incyte Corporation $175.80 01/28/2019 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A Randomized, Double Blind, Placebo Controlled Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids for the Treatment of First Line Acute Graft Versus Host Disease No dispute reported 06/30/2026 666476823
Principal investigator 1 Incyte Corporation $95.50 01/28/2019 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A Randomized, Double Blind, Placebo Controlled Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids for the Treatment of First Line Acute Graft Versus Host Disease No dispute reported 06/30/2026 666476825
Principal investigator 1 Incyte Corporation $11,510.00 01/17/2019 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A Randomized, Double Blind, Placebo Controlled Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids for the Treatment of First Line Acute Graft Versus Host Disease No dispute reported 06/30/2026 666460703
Principal investigator 1 Incyte Corporation $2,529.00 01/17/2019 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A Single Arm, Open Label, Phase 1 Study of Itacitinib in Combination With Calcineurin Inhibitor Based Interventions for the Prophylaxis of Graft Versus Host Disease GRAVITAS 119 No dispute reported 06/30/2026 666460719